Category: Oncotarget

Oncotarget News

Why We Ride: Misha Pletnikov

June 23, 2023

My name is Misha Pletnikov, I am chair of the department of physiology and biophysics in the Jacobs School of Medicine and Biomedical Sciences of the University at Buffalo. I... read more

Oncotarget

Targeting GITR in cancer immunotherapy – there is no perfect knowledge

June 21, 2023

the experience with GITR targeting in patients may inform the development of either novel or next-generation immunotherapy approaches.”BUFFALO, NY- June 21, 2023 – A new research perspective was published in... read more

Figure 4: Variable changes in phosphorylation of S6 kinase 1 was observed in both cohorts. metformin

Oncotarget

Metformin’s Role in Preventing Metabolic Syndrome during Androgen Deprivation Therapy: A Phase II Study

June 20, 2023

we found no impact of the addition of metformin to [androgen deprivation] therapy on risk of metabolic syndrome associated with castration therapy and no additional anti-tumor effects.”BUFFALO, NY- June... read more

Oncotarget

Oncotarget Sponsors 2023 Ride for Roswell

June 19, 2023

Oncotarget's publisher, Impact Journals, is sponsoring Team Open Access in the annual cycling event to end cancer: The Ride for Roswell. This fundraiser is hosted by Roswell Park Comprehensive Cancer... read more

Figure 1: Proposed pathway of ACSL4-mediated stimulation of quadruple negative breast cancer cells

Oncotarget

ACSL4: Biomarker, Mediator and Target in Quadruple Negative Breast Cancer

June 14, 2023

ACSL4 has been demonstrated to play a pivotal role in both normal physiology as well as in a variety of disease states, including breast and other cancers.”BUFFALO, NY- June... read more

Figure 6: LP-284 is selectively lethal in cells with TC-NER deficiency. non-Hodgkin's lymphoma

Oncotarget

LP-284 Targets Non-Hodgkin’s Lymphoma and DNA Damage Repair Deficiency

June 12, 2023

we demonstrated the new acylfulvene compound LP-284 has anti-tumor activity including nanomolar potency in fifteen in vitro NHL cell lines and in vivo preclinical NHL models.”BUFFALO, NY- June 12,... read more

Figure 1: Canonical Src regulation involves the transition from an inactive closed state to an active open form.

Oncotarget

Targeting the Src N-Terminal Regulatory Element in Cancer

June 9, 2023

Src is a recognized oncotarget.”BUFFALO, NY- June 9, 2023 – A new research perspective was published in Oncotarget's Volume 14 on May 19, 2023, entitled, “Targeting the Src N-terminal regulatory... read more

Figure 1: Response to docetaxel in second or third line treatment for non-small cell lung cancer after a treatment with chemo-immunotherapy.

Oncotarget

Value of Chemotherapy Post Immunotherapy in Stage IV Non-Small Cell Lung Cancer

June 7, 2023

large multicenter prospective randomized trials are needed to provide the clinical evidence for the use of [chemotherapy] in second line and third-line post [immunotherapy] failure.”BUFFALO, NY- June 7, 2023 –... read more

Association of mutation and expression of the brother of the regulator of imprinted sites (BORIS) gene with breast cancer progression

Oncotarget

BORIS Gene Mutation and Expression: Link to Breast Cancer Progression

June 5, 2023

The current study analyzed the correlation between BORIS mutations and the expression of the protein in breast cancer cases.”BUFFALO, NY- June 5, 2023 – A new research paper was published... read more

Figure 1: MALAT1-ASO specifically targets MALAT1-lncRNAs.

Oncotarget

Deconstructing the Role of MALAT1 in MAPK-Signaling in Melanoma

May 30, 2023

In this study, we present novel transcriptional dependencies between MALAT1 and MAPK-pathway-associated genes in melanoma.”BUFFALO, NY- May 30, 2023 – A new research paper was published in Oncotarget's Volume 14... read more